Wattenberg L W, Wiedmann T S, Estensen R D, Zimmerman C L, Galbraith A R, Steele V E, Kelloff G J
Department of Laboratory Medicine and Pathology and College of Pharmaceutics, School of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.
Carcinogenesis. 2000 Feb;21(2):179-82. doi: 10.1093/carcin/21.2.179.
This investigation is part of an effort to develop chemoprevention for carcinogenesis of the lung. It focuses on the efficacy of low doses of synthetic glucocorticoids administered either as single agents or in combination with a second compound, myo-inositol. Glucocorticoids are potent inhibitors of carcinogenesis. The use of low doses is important to avoid potential side-effects. The synthetic glucocorticoid budesonide, administered by aerosol for 20 s three times a week, was studied to determine its effects on benzo[a]pyrene-induced pulmonary adenoma formation in female A/J mice. Two dose levels were employed, 10 and 25 microg/kg body wt. The lower dose produced a 34% reduction in lung tumor formation and the higher dose level a 60% reduction in lung tumors. In additional groups of mice, the effects of 0.3% myo-inositol added to the diet was found to reduce pulmonary tumor formation by 53%. The two agents given in combination resulted in a greater inhibition of lung tumor formation than either by itself. Budesonide at 10 microg/kg body wt plus 0.3% myo-inositol reduced the number of tumors by 60% and budesonide at 25 microg/kg body wt plus 0.3% myo-inositol reduced lung tumor formation by 79%. To determine whether a glucocorticoid other than budesonide would have inhibitory effects in this experimental model, beclomethasone dipropionate administered by aerosol for 20 s three times a week was studied as a single agent and showed almost identical inhibitory properties to budesonide. The doses of the glucocorticoids calculated on a daily basis are within the range of those used widely for control of chronic allergic respiratory diseases in the human. The capacity of low doses of inhaled glucocorticoids to prevent pulmonary neoplasia and the enhancement of this preventive effect by myo-inositol, an essentially non-toxic compound, are findings that should encourage further work to evaluate the applicability of these agents to the prevention of neoplasia of the lung in the human.
本研究是开发肺癌化学预防方法的一部分。它聚焦于低剂量合成糖皮质激素单独使用或与第二种化合物肌醇联合使用的效果。糖皮质激素是致癌作用的有效抑制剂。使用低剂量很重要,以避免潜在的副作用。对通过气雾剂每周给药三次、每次20秒的合成糖皮质激素布地奈德进行了研究,以确定其对雌性A/J小鼠中苯并[a]芘诱导的肺腺瘤形成的影响。采用了两个剂量水平,分别为10和25微克/千克体重。较低剂量使肺肿瘤形成减少了34%,较高剂量水平使肺肿瘤减少了60%。在另外几组小鼠中,发现饮食中添加0.3%肌醇可使肺肿瘤形成减少53%。两种药物联合使用对肺肿瘤形成的抑制作用比单独使用任何一种药物都更大。10微克/千克体重的布地奈德加0.3%肌醇使肿瘤数量减少了60%,25微克/千克体重的布地奈德加0.3%肌醇使肺肿瘤形成减少了79%。为了确定除布地奈德之外的其他糖皮质激素在该实验模型中是否具有抑制作用,对通过气雾剂每周给药三次、每次20秒的丙酸倍氯米松作为单一药物进行了研究,结果显示其抑制特性与布地奈德几乎相同。按每日计算的糖皮质激素剂量在人类用于控制慢性过敏性呼吸道疾病的广泛使用范围内。低剂量吸入糖皮质激素预防肺肿瘤形成的能力以及肌醇(一种基本无毒的化合物)对这种预防效果的增强作用,这些发现应鼓励进一步开展工作,以评估这些药物在人类预防肺癌方面的适用性。